UBE2C identified as a key driver in pancreatic cancer via PI3K/Akt/mTOR pathway
UBE2C is overexpressed in pancreatic cancer, promoting progression through the PI3K/Akt/mTOR pathway.
Phase III
pancreatic cancer therapies
Status
Active
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The identification of UBE2C as a key driver in pancreatic cancer progression highlights a significant opportunity for novel therapeutic interventions. This could reshape treatment paradigms and necessitate a reevaluation of existing therapies targeting the PI3K/Akt/mTOR pathway.
Recommended action
Humanexa recommends Investigate.
Analysis
Monitor developments in UBE2C-targeted therapies and clinical trials assessing its role as a biomarker.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.